Data support the potential of CFTX-2034 as a first-in-class treatment for PBH and advancement toward Phase 1 clinical development Ghent, Belgium – June 15, 2026 – Confo Therapeutics, a clinical-stage ...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced two poster presentations at the upcoming Endocrine Society’s Annual Meeting (ENDO 2026), taking place June 13-16 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results